
    
      Primary objectives:

      Evaluate the safety and tolerance of CT0180 cells in patients with advanced hepatocellular
      carcinoma within 28 days after the first infusion

      Secondary objectives:

        -  Evaluate the metabolic kinetics of CT0180 cells ; · Evaluate overall safety and
           tolerability ; · Evaluate the initial efficacy of CT0180 cell infusion in the treatment
           of advanced hepatocellular carcinoma with positive Glypican-3（GPC3 ）expression.
    
  